Fixed-Dose Combination Therapy in PAH: Simplifying Upfront Treatment

In "Fixed-Dose Combination Therapy in PAH: Simplifying Upfront Treatment," the experts turn to a practical advance in simplifying initial treatment.

Dr. McLaughlin asks how clinicians start dual therapy in practice. Dr. Channick explains that both approaches are used, with the fixed-dose combination going in up front for many patients and the agents starting separately for others. The choice reflects side effects more than efficacy, because starting one drug at a time and adding the second quickly lets clinicians assess the tolerability of each agent.

Dr. McLaughlin then turns to the macitentan and tadalafil fixed-dose combination, approved by the FDA in 2024. Dr. Vaidya calls it a game changer, because patients are asking for fewer medications and this pill tackles two of four pathways once daily. The supporting A DUE trial enrolled just under 200 patients, used pulmonary vascular resistance as its primary endpoint, and was clearly positive. In her experience prior authorization has generally succeeded and cost has not burdened patients, and the single pill makes it easier to discuss adding a third and fourth pathway within months.

In a follow-up question, Dr. McLaughlin asks Dr. Channick which patients should start on the combination. He would offer it to most patients with Group 1 PAH who are candidates for an endothelin receptor antagonist plus a PDE5 inhibitor, noting that two strengths are available. He is more cautious with older patients at risk of edema or those with lower blood pressure, and he starts one drug at a time. If both agents are tolerated and side effects such as edema or headache are manageable, he moves quickly to the combination.

Dr. Kim agrees that the combination is now standard care. Insurance, logistics, and side effects influence timing, but most patients who are not high risk can use it, and he emphasizes that pill burden affects adherence.

The next episode in this series, "Treating Established vs Newly Diagnosed PAH: Confirming the Diagnosis First," features Dr. Kim on diagnosing and treating referred patients versus those new to the clinic.